Terns Pharmaceuticals

Inactive

TERN (NasdaqGS)

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on small-molecule therapies for cancer and metabolic diseases. It is advancing TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1/2 for chronic myeloid leukemia. It is also developing TERN-501, a thyroid hormone receptor beta agonist in Phase IIa for metabolic dysfunction-associated steatohepatitis, and TERN-801 GIPR modulators for obesity. Founded in 2016, based in Foster City, California.